Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study

BACKGROUND: The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55–69. Knowing how the potential benefits and harms of screening vary by an individual’s risk of developing prostate cancer could infor...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS Med
Autors principals: Callender, Tom, Emberton, Mark, Morris, Steve, Eeles, Ros, Kote-Jarai, Zsofia, Pharoah, Paul D. P., Pashayan, Nora
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2019
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6924639/
https://ncbi.nlm.nih.gov/pubmed/31860675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1002998
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars